← Back to Manufacturing / Production
MANUFACTURING / PRODUCTION / PROCESS

Pharma / Biopharma

Leader: Eli Lilly — 8.5% S1 · 23.0% CR3

S1
8.5%
leader
CR3
23.0%
top 3 combined
HHI
195
Unconcentrated
MARKET SIZE
$600B
Global

How this is calculated

FORMULA
S1 = Eli Lilly revenue / total revenue = 8.5%
CR3 = Eli Lilly + Johnson & Johnson Innovative Medicine + Merck & Co = 23.0%
HHI = Σ(share²) = 195 (Unconcentrated (HHI < 1,500))
DENOMINATOR
Revenue — $600B (Global)
Global innovative + generic prescription pharmaceutical revenue.
Size from: IQVIA Institute for Human Data Science
TOP 3 PLAYERS
#1Eli Lilly8.5%
#2Johnson & Johnson Innovative Medicine7.5%
#3Merck & Co7.0%
METHODOLOGY NOTE
2024 was transformational. Eli Lilly's Mounjaro/Zepbound (GLP-1) drove revenue to $45B (US ~$31B) — fastest-growing US Rx. AbbVie's Humira lost biosimilar exclusivity and dropped meaningfully. Pfizer's COVID revenues collapsed. Updated 2024 US Rx ranking: Eli Lilly > J&J Innovative Medicine ($32B US) > Merck (~$30B US, Keytruda dominant) > AbbVie ($40B US but declining) > Pfizer (~$25B ex-COVID). The Lilly #1 call reflects 2024 trajectory and the GLP-1 wave defining current US Rx dynamics. CR3 ~23%, higher than previously stated, but US Rx remains genuinely fragmented relative to most other categories. Denominator: US prescription drug market ~$530B (IQVIA).
SOURCES
Year: 2025
Geo: Global
Firms: Hundreds globally; top-3 reflect 2024 GLP-1 transformation

Historical S1 / CR3 trajectory

1990S1: 8%CR3: 22%Pre-M&A consolidation
2000S1: 7.5%CR3: 20%Big pharma peak
2010S1: 7%CR3: 19%Generic pressure + biosimilars
2020S1: 6.8%CR3: 18.5%Biosimilar wave
2025S1: 6.5%CR3: 18%Innovative / Kenvue split

Labor economics

REV / EMPLOYEE (leader)
$0.6M
industry avg $0.5M
SG&A % (leader)
26%
of revenue

J&J FY2024 SG&A 25.7% on $88.8B; salesforce + DTC marketing intensity

See full Labor & AI analysis →

Related markets

Specialty Chemicals
Dow
5.0%
CR3 12.0%
Petroleum Refining
Marathon Petroleum
17.0%
CR3 42.0%
Paper & Packaging
Smurfit Westrock
12.0%
CR3 22.5%
Plastics & Rubber
Amcor (incl. Berry)
11.0%
CR3 16.5%
Glass Manufacturing
O-I Glass
18.0%
CR3 40.0%

Source Quality Hierarchy

Every market has a primary source plus 1–3 validation sources. Revenue numerators come from SEC 10-K filings; denominators validated against the Economic Census where available.

TIER 1Authoritative anchorsGovernment data + SEC filings
US Economic Census (data.census.gov) · SEC EDGAR / Company 10-Ks · BEA Industry Value-Added (FRED) · BLS QCEW · USGS Mineral Commodity Summaries · EIA Refinery Capacity Report · FDA device listings
TIER 2Leading commercial trackersIndustry-standard paid trackers
IDC Semiannual Software Tracker · Gartner Market Share & Magic Quadrant · IBISWorld NAICS reports · StatCounter Global Stats · eMarketer / Insider Intelligence · Synergy Research Group
TIER 3Category specialistsBest-in-class niche authorities
SIPRI (aerospace & defense) · IQVIA (pharma) · TrendForce (semiconductors) · CIMdata (CAD/PLM) · Nilson Report (payments) · Am Law 100 (legal) · ENR Top 500 (A&E) · AM Best (insurance) · SIA (staffing) · Ad Age (agencies) · Barron's / Cerulli (wealth) · Evaluate MedTech · Nielsen Gauge (streaming) · Gridwise (ride-hail) · Bloomberg Second Measure (delivery) · RC Top 100 (roofing) · SDM Top 100 (fire/safety) · Big 4 annual reports · ALM Intelligence (consulting)

Data vintage: Q2 2025 research compilation. Labels updated 2026-Q2. Tier 1 sources refreshed from FY2025 SEC filings where available. For full methodology see the Methodology page.